ACI
PBYI icon

AMP Capital Investors’s Puma Biotechnology PBYI Stock Holding History

AMP Capital Investors’s Portfolio PBYI Stock Details PBYI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-6,479
Closed -$463K – 1254
2015
Q3 		$463K Buy
6,479
+900
+16% +$85.1K ﹤0.01% 978
2015
Q2 		$633K Buy
+5,579
New +$1.01M ﹤0.01% 955

Other funds holding PBYI

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Grantham, Mayo, Van Otterloo & Co (GMO)
Grantham, Mayo, Van Otterloo & Co (GMO) Boston, Massachusetts $44.4B AUM 36.05% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

AMP Capital Investors's PBYI Position: Q4 2015 in Review

AMP Capital Investors sold out of Puma Biotechnology (PBYI) in Q4 2015, closing a stake of 6,479 shares — an estimated $463K sold.

AMP Capital Investors first reported a position in PBYI in Q2 2015 and held it in 2 quarters. The position peaked at $633K in Q2 2015. 133 funds tracked by Wall St. Rank hold PBYI as of Q4 2015.

  • AMP Capital Investors reported no remaining Puma Biotechnology position as of Q4 2015 after selling out during the quarter.
  • AMP Capital Investors sold 6,479 Puma Biotechnology shares in Q4 2015, an estimated $463K.
  • AMP Capital Investors first reported a position in Puma Biotechnology in Q2 2015 and held it in 2 quarters.
  • AMP Capital Investors's Puma Biotechnology position peaked at $633K in Q2 2015.
  • 133 funds tracked by Wall St. Rank held Puma Biotechnology as of Q4 2015.

Based on AMP Capital Investors's 13F filing for Q4 2015, filed 16 Feb 2016.